Assignee
METRO INT BIOTECH LLC
US·19 granted patents·3 pending applications·148 citations·filing 2016–2025
Top patents by PatentIndex Score
22 records- 0196US10618927B1Compositions and methods for modulation of nicotinamide adenine dinucleotideMETRO INT BIOTECH LLC·Filed 2019·Granted Apr 14, 2020·29 cites·19 claims
- 0295US11878027B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2022·Granted Jan 23, 2024·2 cites·13 claims
- 0395US10548913B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2018·Granted Feb 4, 2020·18 cites·29 claims
- 0494US10233208B1Crystal forms of beta-nicotinamide mononucleotideMETRO INT BIOTECH LLC·Filed 2018·Granted Mar 19, 2019·14 cites·16 claims
- 0594US9919003B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2017·Granted Mar 20, 2018·16 cites·37 claims
- 0694US9855289B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2016·Granted Jan 2, 2018·19 cites·35 claims
- 0793US11787830B2Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and useMETRO INT BIOTECH LLC·Filed 2023·Granted Oct 17, 2023·3 cites·21 claims
- 0893US11059847B2Crystal forms of β-nicotinamide mononucleotideMETRO INT BIOTECH LLC·Filed 2019·Granted Jul 13, 2021·9 cites·10 claims
- 0992US11952396B1Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and useMETRO INT BIOTECH LLC·Filed 2023·Granted Apr 9, 2024·2 cites·18 claims
- 1092US10392416B2Crystal forms of beta-nicotinamide mononucleotideMETRO INT BIOTECH LLC·Filed 2019·Granted Aug 27, 2019·10 cites·24 claims
- 1192US10392415B2Crystal forms of β-nicotinamide mononucleotideMETRO INT BIOTECH LLC·Filed 2016·Granted Aug 27, 2019·10 cites·17 claims
- 1290US11939348B2Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotideMETRO INT BIOTECH LLC·Filed 2020·Granted Mar 26, 2024·2 cites·19 claims
- 1390US11464796B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2019·Granted Oct 11, 2022·6 cites·12 claims
- 1487US12485135B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2023·Granted Dec 2, 2025·0 cites·12 claims
- 1586US11180521B2Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereofMETRO INT BIOTECH LLC·Filed 2019·Granted Nov 23, 2021·7 cites·19 claims
- 1685US11279727B2Anti-viral compounds and methods of useMETRO INT BIOTECH LLC·Filed 2021·Granted Mar 22, 2022·1 cites·8 claims
- 1775US12391721B2Crystal forms of beta-nicotinamide mononucleotideMETRO INT BIOTECH LLC·Filed 2025·Granted Aug 19, 2025·0 cites·15 claims
- 1868US12516081B2Anti-viral compounds and methods of useMETRO INT BIOTECH LLC·Filed 2021·Granted Jan 6, 2026·0 cites·20 claims
- 1967US11878994B1Compositions for treatment of inflammationMETRO INT BIOTECH LLC·Filed 2023·Granted Jan 23, 2024·0 cites·30 claims
- 2060US2025066413A1Compositions for treatment of inflammationMETRO INT BIOTECH LLC·Filed 2022·Application pending·0 cites
- 2157US2023255994A1Treatment of covid-19 and/or acute kidney injuryMETRO INT BIOTECH LLC·Filed 2021·Application pending·0 cites
- 2249US2022324899A1Compounds and compositions for differential modulation of nicotinamide adenine dinucleotideMETRO INT BIOTECH LLC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when METRO INT BIOTECH LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →